Emerging evidence indicates that perturbation of oncogenic signaling pathways may also compromise anti‐tumor immune responses, thereby contributing to resistance against molecularly targeted therapies.[35] Here we demonstrated that refractory to CDK9i might be associated with compensatory ERK‐MYC activation, recovery of pro‐oncogene transcription, infiltration of pro‐tumoral TAMs and neutrophils, and tumor angiogenesis. This evidence concerns the gene MAPK1 and neoplasm.